Results for tag: "Cangrelor"

Cangrelor is a cardiovascular drug used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). It is a direct-acting, reversible, and potent inhibitor of the platelet P2Y12 receptor. Cangrelor is administered intravenously and works by blocking the binding of adenosine diphosphate (ADP) to the P2Y12 receptor, thus preventing platelet aggregation. It is used in combination with aspirin and other antithrombotic agents to reduce the risk of thrombotic cardiovascular events in patients with ACS. The Cangrelor market is a rapidly growing segment of the cardiovascular drugs market. It is expected to witness strong growth in the coming years due to the increasing prevalence of ACS and the growing demand for effective treatments. The market is also driven by the increasing adoption of Cangrelor in clinical practice and the availability of generic versions of the drug. Some of the key players in the Cangrelor market include AstraZeneca, Pfizer, Sanofi, Merck, and Bristol-Myers Squibb. Show Less Read more